Adult fibrosarcoma
diseaseOn this page
Also known as adult fibrosarcoma (disease)fibrosarcomafibrosarcoma (disease) of adults
Summary
Adult fibrosarcoma (MONDO:0002676) is a disease and 24 clinical trials. Top therapeutic interventions include pazopanib, ifosfamide, and dexrazoxane. A subtype of conventional fibrosarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 24
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | adult fibrosarcoma |
| Mondo ID | MONDO:0002676 |
| DOID | DOID:3516 |
| NCIT | C7809 |
| UMLS | C0278595 |
| MedGen | 75840 |
| GARD | 0023209 |
| Is cancer (heuristic) | no |
Also known as: adult fibrosarcoma · adult fibrosarcoma (disease) · fibrosarcoma · fibrosarcoma (disease) of adults
Data availability: 109 cell lines.
Disease family
This is a subtype of conventional fibrosarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › mesenchymal cell neoplasm › fibroblastic neoplasm › fibrosarcoma › conventional fibrosarcoma › adult fibrosarcoma
Related subtypes (1): congenital fibrosarcoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 24.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 15 |
| Not specified | 3 |
| PHASE1/PHASE2 | 2 |
| PHASE1 | 2 |
| PHASE3 | 1 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02180867 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery |
| NCT00346164 | PHASE3 | COMPLETED | Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma |
| NCT06277154 | PHASE2 | RECRUITING | MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma |
| NCT06638931 | PHASE2 | RECRUITING | Agnostic Therapy in Rare Solid Tumors |
| NCT06849986 | PHASE2 | RECRUITING | IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS) |
| NCT00003292 | PHASE2 | TERMINATED | S9624 Ifosfamide in Treating Patients With Meningeal Tumors |
| NCT00084630 | PHASE2 | COMPLETED | Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans |
| NCT00112463 | PHASE2 | COMPLETED | Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma |
| NCT00141765 | PHASE2 | COMPLETED | Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers |
| NCT00356031 | PHASE2 | COMPLETED | Bevacizumab and Radiation Therapy for Sarcomas |
| NCT00400569 | PHASE2 | COMPLETED | Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma |
| NCT00503295 | PHASE2 | COMPLETED | Safety and Efficacy Study of REOLYSIN® in the Treatment of Bone and Soft Tissue Sarcomas Metastatic to the Lung |
| NCT00659360 | PHASE2 | COMPLETED | AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma |
| NCT01154452 | PHASE1/PHASE2 | COMPLETED | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma |
| NCT01532687 | PHASE2 | COMPLETED | Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma |
| NCT01962103 | PHASE1/PHASE2 | COMPLETED | Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors |
| NCT02584309 | PHASE2 | COMPLETED | Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma |
| NCT03651375 | PHASE2 | UNKNOWN | Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall |
| NCT03989596 | PHASE2 | UNKNOWN | Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas |
| NCT00720174 | PHASE1 | COMPLETED | Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue Sarcoma |
| NCT03009201 | PHASE1 | COMPLETED | Ribociclib and Doxorubicin in Treating Patients With Metastatic or Advanced Soft Tissue Sarcomas That Cannot Be Removed by Surgery |
| NCT06387485 | Not specified | RECRUITING | A Study to Evaluate the Utilization of 3D Printed Models in Pre-Operative Planning |
| NCT06526897 | Not specified | NOT_YET_RECRUITING | Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma |
| NCT06662734 | Not specified | COMPLETED | Infantile Versus Adult-type Fibrosarcoma and the Risk of Multiple Primary Malignancies |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| PAZOPANIB | 4 | 6 |
| IFOSFAMIDE | 4 | 5 |
| DEXRAZOXANE | 4 | 3 |
| IMATINIB | 4 | 1 |
| ROMIDEPSIN | 4 | 1 |
| SUNITINIB MALATE | 4 | 1 |
| VISMODEGIB | 4 | 1 |
| SARACATINIB | 3 | 1 |
| CIXUTUMUMAB | 2 | 1 |
| CHEMBL4068768 | 0 | 2 |
| CHEMBL4171277 | 0 | 2 |
| CHEMBL4066465 | 0 | 1 |
| CHEMBL3109278 | 0 | 1 |
| CHEMBL4438584 | 0 | 1 |